DrugPatentWatch Database Preview
BANZEL Drug Profile
Which patents cover Banzel, and when can generic versions of Banzel launch?
Banzel is a drug marketed by Eisai Inc and is included in two NDAs. There are three patents protecting this drug and two Paragraph IV challenges.
The generic ingredient in BANZEL is rufinamide. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rufinamide profile page.
Summary for BANZEL
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 2 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 78 |
| Patent Applications: | 374 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for BANZEL |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for BANZEL |
| DailyMed Link: | BANZEL at DailyMed |
Synonyms for BANZEL
| 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazol-4-carboxamide |
| 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
| 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4 carboxamide |
| 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide |
| 1-[(2,6-difluorophenyl)methyl]-4-triazolecarboxamide |
| 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide |
| 1-[[2,6-bis(fluoranyl)phenyl]methyl]-1,2,3-triazole-4-carboxamide |
| 106308-44-5 |
| 1H-1,2,3-Triazole-4-carboxamide, 1-((2,6-difluorophenyl)methyl)- |
| 1H-1,2,3-Triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]- |
| 308R445 |
| 3B1-000291 |
| A801414 |
| AB0017630 |
| AB00918347_06 |
| AB00918347-05 |
| AB1008455 |
| AC-1429 |
| AC1L2V8C |
| AKOS005145897 |
| AN-598 |
| API0012839 |
| AS-13861 |
| AS07135 |
| Banzel (TN) |
| Banzel, Rufinamide |
| BC224496 |
| C10H8F2N4O |
| CAS-106308-44-5 |
| CCG-222100 |
| Cgp 33101 |
| CGP-33101 |
| CGP33101 |
| CHEBI:134966 |
| CHEMBL1201754 |
| CS-1455 |
| CTK8E9248 |
| D02OBK |
| D05775 |
| D0MD2L |
| DB06201 |
| DSSTox_CID_26506 |
| DSSTox_GSID_46506 |
| DSSTox_RID_81675 |
| DTXSID1046506 |
| E 2080 |
| E-2080 |
| E2080 |
| EN300-120881 |
| F0001-2404 |
| FT-0656828 |
| GTPL7470 |
| HE005618 |
| HE293185 |
| HE293186 |
| HMS2232M19 |
| HMS3262O14 |
| HMS3371A06 |
| HMS3651O05 |
| HY-A0042 |
| I06-1425 |
| Inovelon |
| Inovelon/Banzel |
| J-001568 |
| J10459 |
| KS-00000YSQ |
| LP00796 |
| MCULE-6872329028 |
| MFCD00865314 |
| MLS001332513 |
| MLS001332514 |
| MolPort-005-942-441 |
| NCGC00165883-01 |
| NCGC00165883-02 |
| NCGC00165883-03 |
| NCGC00165883-04 |
| NCGC00261481-01 |
| POGQSBRIGCQNEG-UHFFFAOYSA-N |
| PubChem14896 |
| Q503 |
| R0143 |
| RT-015464 |
| RUF 331 |
| RUF-331 |
| Rufinamide |
| Rufinamide (Banzel) |
| Rufinamide (JAN/USAN/INN) |
| Rufinamide (USAN/INN) |
| Rufinamide [USAN:INN:BAN] |
| Rufinamide, >=98% (HPLC), powder |
| Rufinamide, United States Pharmacopeia (USP) Reference Standard |
| s1256 |
| SBB070637 |
| SCHEMBL230448 |
| SMR000857122 |
| SR-01000842156 |
| SR-01000842156-4 |
| SYN-111 |
| SYN111 |
| Tox21 112267 |
| Tox21_112267 |
| Tox21_112267_1 |
| Tox21_500796 |
| UNII-WFW942PR79 |
| W-5135 |
| WFW942PR79 |
| Xilep |
| Z1541638521 |
| ZB000661 |
| ZINC7782 |
US Patents and Regulatory Information for BANZEL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | BANZEL | rufinamide | SUSPENSION;ORAL | 201367-001 | Mar 3, 2011 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Eisai Inc | BANZEL | rufinamide | TABLET;ORAL | 021911-002 | Nov 14, 2008 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Eisai Inc | BANZEL | rufinamide | TABLET;ORAL | 021911-001 | Nov 14, 2008 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Eisai Inc | BANZEL | rufinamide | TABLET;ORAL | 021911-002 | Nov 14, 2008 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for BANZEL
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 100 mg, 200 mg and 400 mg | ➤ Subscribe | ➤ Sign Up |
| ➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | ➤ Sign Up |
International Patents for BANZEL
Supplementary Protection Certificates for BANZEL
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0284 | Netherlands | ➤ Sign Up | 300284, 20180608, EXPIRES: 20220115 |
| C/GB07/041 | United Kingdom | ➤ Sign Up | PRODUCT NAME: CRYSTAL MODIFICATION A OF RUFINAMIDE; REGISTRATION NO/DATE: EU/1/06/378/001 - 015 |
| C0037 | France | ➤ Sign Up | PRODUCT NAME: MODIFICATION CRISTALLINE A DU RUFINAMIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/378/001 DU 20070116; REGISTRATION NO/DATE AT EEC: EU/1/06/378/001-016 DU 20070116 |
| C026/2007 | Ireland | ➤ Sign Up | SPC026/2007: 20071026, EXPIRES: 20220115 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
